Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from NEJM

New Alzheimer's drug shows modest slowing of early disease progression

Scientists are cautiously optimistic about the promise of an experimental drug shown to modestly slow the progression of Alzheimer's disease in some patients.

ABC News · Dec 1, 2022

Newly identified Langya virus tracked after China reports dozens of cases

Newly identified Langya virus tracked after China reports dozens of cases

Virus, which causes symptoms including fever, fatigue, cough, loss of appetite and muscle aches, is believed to have spread from animals to humans

The Guardian - AU · Aug 10, 2022

Ionis Pharma Announces Publication Of Positive Donidalorsen Data For Angioedema Attacks

Ionis Pharma Announces Publication Of Positive Donidalorsen Data For Angioedema Attacks

Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced the publication of Phase 2 data for donidalorsen in the New England Journal of Medicine (NEJM). Donidalorsen is an investigational antisense medicine under development for hereditary angioedema (HAE), a disorder characterized by recurrent episodes of severe swelling. In the Phase 2 study, donidalorsen demonstrated a 90% reduction in…

Benzinga · Mar 17, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

GSK/Vir Biotech's COVID-19 Antibody Associated With Resistance Mutations, New Research Shows

According to new research in Australia, some people have developed sotrovimab-resistant mutations following infusions with the GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc (NASDAQ:VIR) monoclonal antibody with COVID-19 infection. Data shows that the mutations have been associated with a reduction by a factor of 100 to 297 in neutralization by sotrovimab. "These data show the persistence…

Benzinga · Mar 11, 2022

NEJM Publication Shows Novartis' Kisqali With Longest Median Overall Survival In Breast Cancer Setting

The New England Journal of Medicine (NEJM) published data from Phase 3 MONALEESA-2 trial of Novartis AG's (NYSE:NVS) Kisqali (ribociclib) plus letrozole demonstrating a statistically significant improvement in overall survival. MONALEESA-2 overall survival data were first presented at the European Society for Medical Oncology Congress in September 2021. The NEJM publication includes additional analyses substantiating the longest median…

Benzinga · Mar 10, 2022

1 2

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

New England Journal of Medicine

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play